An interventional study of Standard Care Only and Custom Insole + Standard Care in Diabetic Foot Ulcer, sponsored by University of Lahore. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of Lahore · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetic Foot with a site in Pakistan — 5 open to participants now, 7 under way, 1 of them phase 3. Diabetic Foot · Pakistan.
Among the 17 studies in Diabetic Foot with a site in Pakistan, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 11th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →5 of the 17 studies in Diabetic Foot with a site in Pakistan are open now. Recruiting first, the newest first:
United Medical and Dental College · Sites in Pakistan
Ages 18+
University of the Punjab · Sites in Pakistan
Ages 20–60
Abbas Institute of Medical Sciences · Sites in Pakistan
Ages 18–70
Shifa International Hospital · Sites in Pakistan
Ages 18–80
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 159 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 94 across the 16 interventional studies, 110 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
University of Lahore is the lead sponsor of 237 studies on the registry; 47 are open to participants now.
University of Lahore has 2 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetic Foot with a site in Pakistan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488247Phase 3United Medical and Dental CollegePhase IIb and III Safety and Efficacy Study Chlorin E6 Gel Photodynamic Therapy for Diabetic Foot Ulcers: | 2027-09 |
| NCT07109895University of LahoreCustom Insole With Transcutaneous Electrical Nerve Stimulation on Clinical Outcomes of Diabetic Foot Ulcers | 2026-12-30 |
| NCT07840300Shifa International HospitalActivity Reduction vs Advice for Plantar Hotspots in Diabetes | 2027-04-01 |
| NCT07898202Abbas Institute of Medical SciencesComparison of Negative Pressure Wound Therapy Versus Moist Wound Dressing in Diabetic Foot Ulcer Patients | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Diabetic Foot with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetic foot ulcers (DFUs) are one of the serious complications of diabetes, typically resulting from neuropathy or peripheral arterial disease, and can often lead to amputation. It affects approximately 6.3% of people with diabetes globally. In Pakistan, the overall prevalence of DFUs is 16.83%, with a slightly higher rate in females. Diabetic foot ulcers are the main reason for lower extremity amputation (LEA) with non-traumatic origin, hospitalization, healthcare costs, and mortality.
Diabetic foot ulcers (DFUs) are a significant complication of diabetes, carry a high risk of amputation and disability, and affect around 6.3% of diabetic patients globally. Risk factors for DFUs include pre-ulcerative lesions, mechanical pressure, restricted mobility, and poor glycemic control. Peripheral neuropathy plays a crucial role in DFU development, causing structural and functional changes in the foot.
Offloading interventions, such as prefabricated orthotics and custom insoles, are essential for preventing DFU development and promoting ulcer healing. Physiotherapy modalities like therapeutic exercise and electrotherapy can assist in tissue repair and pain management. Orthotic management complements rehabilitation efforts, potentially reducing the risk of wound development. Further research on the combined benefits of transcutaneous electrical nerve stimulation (TENS) and customized insoles for DFUs is necessary to enhance clinical outcomes.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
11. Dementia or impaired cognitive function
Participants will receive standard care for diabetic foot ulcers.
Other: Standard Care Only
Participants will receive a custom insole along with standard care.
Other: Custom Insole + Standard Care
Participants will receive TENS therapy, a custom insole, and standard care.
Other: TENS + Custom Insole + Standard Care
Standard care includes routine wound debridement, moist wound dressings infection control, glycemic management, vascular assessment, and patient education in line with international DFU management guidelines.
The experimental group will receive customised polyethene foam insoles with a Poron top layer along with standard care.
Participants in this group will receive a combination of transcutaneous electrical nerve stimulation (TENS), custom-made insole therapy, and standard care for diabetic foot ulcers (DFUs).
Wound Healing
Patients will be assessed for ulcer dimensions by using a simple ruler method. Length and width will be noted using a simple ruler method.
Time frame: Wound dimensions will be measured at baseline, and change in length and width will be measured at the 4th week, 8th week, and 12th week of the treatment session.
Risk of fall
The Tinetti Scale will be used to measure the risk of fall. The final score of the scale is 28 points, and the interpretation is as follows: 25-28 = low risk of falls; 19-24 = moderate risk of falls; and \<19 = high risk of falls.
Time frame: Risk of fall will be measured at baseline, and change in status will be measured at the 4th week, 8th week, and 12th week of the treatment session.
Dynamic Balance:
The time up and go (TUG) scale will be used for measuring dynamic balance. A time score of ≤10 seconds is considered normal, and a time of ≥14 seconds has been shown to indicate a high risk of falls.
Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.
Pain Intensity
Pain intensity will be measured using a visual analogue scale. It is an 11-point scale where "0" indicates no pain and "10" indicates the worst possible pain.
Time frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.
Toe Muscle Strength
The paper grip test (PGT) will be used to measure toe muscle strength.
Time frame: Toe Muscle Strength will be measured at baseline, and change in strength will be measured at the 4th week, 8th week, and 12th week of the treatment session.
Plan to share: Yes
Supporting information: Study protocol
Time frame: Will be share after publication
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jan 2026 → Dec 2026 and completion Jan 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.